Starting May 15, China will mandate foreign pharmaceutical companies to appoint local representatives within the country, underscoring the need for our firms to bolster their regulatory compliance capabilities.
The Korea International Trade Association (KITA) released this analysis in a report on the Revised Implementation Regulations of China’s Drug Administration Law on Friday.
This comprehensive update, the first since the law’s establishment in 2002, introduces several key changes: streamlining drug research, development, and registration processes; expanding the use of overseas clinical trial data; implementing fast-track reviews and data protection for innovative drugs; strengthening responsibilities for Marketing Authorization Holders (MAH); and tightening regulations on drug production, distribution, and online sales.
The report highlights that the most significant changes involve systematizing drug research and development (R&D) and registration processes, while clearly defining expedited review and conditional approval systems in legal terms.
The ordinance will also broaden the acceptance of overseas clinical trial data and allow exemptions for bridging studies. This is expected to simplify the new drug approval process for global pharmaceutical companies in China, particularly benefiting those conducting multinational clinical trials (MRCT).
Moreover, the introduction and codification of market exclusivity periods and data protection systems will enhance intellectual property safeguards.
Notably, the MAH system has been reinforced, expanding corporate accountability. Foreign companies without a local presence in China must now designate a local representative, include the representative’s information on drug labels, and establish robust quality control and post-market risk management systems.
The report states that these amendments aim to formalize and strengthen oversight of China’s drug regulatory framework while fostering innovation and boosting industry competitiveness. It also emphasizes that as regulations on data transfer and quality management obligations have intensified for U.S. pharmaceutical and biotech companies, there’s an urgent need to establish local compliance systems and thoroughly verify adherence to these new regulations.
Lee Bong-geol, director of KITA’s Beijing office, observed that as China overhauls its drug regulations, it’s creating both new market opportunities and regulatory challenges. It’s companies must reassess their market entry strategies in light of these significant regulatory shifts.